Publications

  1. das Neves SP, Delivanoglou N, Ren Y, Cucuzza CS, Makuch M, Almeida F, Sanchez G, Barber MJ, Rego S, Schrader R, Faroqi AH, Thomas JL, McLean PJ, Oliveira TG, Irani SR, Piehl F, Da Mesquita S. Meningeal lymphatic function promotes oligodendrocyte survival and brain myelination. Immunity. 2024 Oct 8; 57 (10):2328-2343.e8 Epub 2024 Aug 31
    View PubMed
  2. Jin Y, Li F, Li Z, Ikezu TC, O'Leary J, Selvaraj M, Zhu Y, Martens YA, Koga S, Santhakumar H, Li Y, Lu W, You Y, Lolo K, DeTure M, Beasley AI, Davis MD, McLean PJ, Ross OA, Kanekiyo T, Ikezu T, Caulfield T, Carr J, Wszolek ZK, Bu G, Dickson DW, Zhao N. Modeling Lewy body disease with SNCA triplication iPSC-derived cortical organoids and identifying therapeutic drugs. Sci Adv. 2024 Sep 13; 10 (37):eadk3700 Epub 2024 Sept 11
    View PubMed
  3. Gupta K, Perkerson RB 3rd, Parsons TM, Angom R, Amerna D, Burgess JD, Ren Y, McLean PJ, Mukhopadhyay D, Vibhute P, Wszolek ZK, Zubair AC, Quinones-Hinojosa A, Kanekiyo T. Secretome from iPSC-derived MSCs exerts proangiogenic and immunosuppressive effects to alleviate radiation-induced vascular endothelial cell damage. Stem Cell Res Ther. 2024 Jul 29; 15 (1):230 Epub 2024 July 29
    View PubMed
  4. Olney KC, Rabichow BE, Wojtas AM, DeTure M, McLean PJ, Dickson DW, Chang R, Ross OA, Fryer JD. Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer's disease. Brain. 2024 Jun 25 Epub 2024 June 25
    View PubMed
  5. Agarwal K, Backler W, Bayram E, Bloom L, Boeve BF, Cha JH, Denslow M, Ferman TJ, Galasko D, Galvin JE, Gomperts SN, Irizarry MC, Kantarci K, Kaushik H, Kietlinski M, Koenig A, Leverenz JB, McKeith I, McLean PJ, Montine TJ, Moose SO, O'Brien JT, Panier V, Ramanathan S, Ringel MS, Scholz SW, Small J, Sperling RA, Taylor A, Taylor JP, Ward RA, Witten L, Hyman BT. Lewy body dementia: Overcoming barriers and identifying solutions. Alzheimers Dement. 2024 Mar; 20 (3):2298-2308 Epub 2024 Jan 24
    View PubMed
  6. Kaya ZB, Santiago-Padilla V, Lim M, Boschen SL, Atilla P, McLean PJ. Optimizing SH-SY5Y cell culture: exploring the beneficial effects of an alternative media supplement on cell proliferation and viability. Sci Rep. 2024 Feb 27; 14 (1):4775
    View PubMed
  7. Basu S, Song M, Adams L, Jeong I, Je G, Guhathakurta S, Jiang J, Boparai N, Dai W, Cardozo-Pelaez F, Tatulian SA, Han KY, Elliott J, Baum J, McLean PJ, Dickson DW, Kim YS. Transcriptional mutagenesis of alpha-synuclein caused by DNA oxidation in Parkinson's disease pathogenesis. Acta Neuropathol. 2023 Nov; 146 (5):685-705 Epub 2023 Sept 23
    View PubMed
  8. Lim MJ, Boschen SL, Kurti A, Castanedes Casey M, Phillips VR, Fryer JD, Dickson D, Jansen-West KR, Petrucelli L, Delenclos M, McLean PJ. Investigating the Pathogenic Interplay of Alpha-Synuclein, Tau, and Amyloid Beta in Lewy Body Dementia: Insights from Viral-Mediated Overexpression in Transgenic Mouse Models. Biomedicines. 2023 Oct 22; 11 (10)
    View PubMed
  9. Burgess JD, Amerna D, Norton ES, Parsons TM, Perkerson RB 3rd, Faroqi AH, Wszolek ZK, Guerrero Cazares H, Kanekiyo T, Delenclos M, McLean PJ. A mutant methionyl-tRNA synthetase-based toolkit to assess induced-mesenchymal stromal cell secretome in mixed-culture disease models. Stem Cell Res Ther. 2023 Oct 5; 14 (1):289 Epub 2023 Oct 05
    View PubMed
  10. Hou X, Chen TH, Koga S, Bredenberg JM, Faroqi AH, Delenclos M, Bu G, Wszolek ZK, Carr JA, Ross OA, McLean PJ, Murray ME, Dickson DW, Fiesel FC, Springer W. Alpha-synuclein-associated changes in PINK1-PRKN-mediated mitophagy are disease context dependent. Brain Pathol. 2023 Sep; 33 (5):e13175 Epub 2023 May 31
    View PubMed
  11. Kaya ZB, Karakoc E, McLean PJ, Saka E, Atilla P. Post-inflammatory administration of N-acetylcysteine reduces inflammation and alters receptor levels in a cellular model of Parkinson's disease. FASEB Bioadv. 2023 Jul; 5 (7):263-276 Epub 2023 May 16
    View PubMed
  12. Meneses AD, Koga S, Li Z, O'Leary J, Li F, Chen K, Murakami A, Qiao W, Kurti A, Heckman MG, White L, Xie M, Chen Y, Finch NA, Lim MJ, Delenclos M, DeTure MA, Linares C, Martin NB, Ikezu TC, van Blitterswijk MM, Wu LJ, McLean PJ, Rademakers R, Ross OA, Dickson DW, Bu G, Zhao N. APOE2 Exacerbates TDP-43 Related Toxicity in the Absence of Alzheimer Pathology. Ann Neurol. 2023 Apr; 93 (4):830-843 Epub 2023 Jan 10
    View PubMed
  13. Fagen SJ, Burgess JD, Lim MJ, Amerna D, Kaya ZB, Faroqi AH, Perisetla P, DeMeo NN, Stojkovska I, Quiriconi DJ, Mazzulli JR, Delenclos M, Boschen SL, McLean PJ. Honokiol decreases alpha-synuclein mRNA levels and reveals novel targets for modulating alpha-synuclein expression. Front Aging Neurosci. 2023; 15:1179086 Epub 2023 Aug 10
    View PubMed
  14. Milanowski LM, Hou X, Bredenberg JM, Fiesel FC, Cocker LT, Soto-Beasley AI, Walton RL, Strongosky AJ, Faroqi AH, Barcikowska M, Boczarska-Jedynak M, Dulski J, Fedoryshyn L, Janik P, Potulska-Chromik A, Karpinsky K, Krygowska-Wajs A, Lynch T, Olszewska DA, Opala G, Pulyk A, Rektorova I, Sanotsky Y, Siuda J, Widlak M, Slawek J, Rudzinska-Bar M, Uitti R, Figura M, Szlufik S, Rzonca-Niewczas S, Podgorska E, McLean PJ, Koziorowski D, Ross OA, Hoffman-Zacharska D, Springer W, Wszolek ZK. Cathepsin B p.Gly284Val Variant in Parkinson's Disease Pathogenesis. Int J Mol Sci. 2022 Jun 25; 23 (13) Epub 2022 June 25
    View PubMed
  15. Jin Y, Li F, Sonoustoun B, Kondru NC, Martens YA, Qiao W, Heckman MG, Ikezu TC, Li Z, Burgess JD, Amerna D, O'Leary J, DeTure MA, Zhao J, McLean PJ, Dickson DW, Ross OA, Bu G, Zhao N. APOE4 exacerbates alpha-synuclein seeding activity and contributes to neurotoxicity in Alzheimer's disease with Lewy body pathology. Acta Neuropathol. 2022 Jun; 143 (6):641-662 Epub 2022 Apr 26
    View PubMed
  16. Cai W, Srivastava P, Feng D, Lin Y, Vanderburg CR, Xu Y, Mclean P, Frosch MP, Fisher DE, Schwarzschild MA, Chen X. Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson's disease. Mol Neurodegener. 2022 Feb 23; 17 (1):16
    View PubMed
  17. Kolicheski A, Turcano P, Tamvaka N, McLean PJ, Springer W, Savica R, Ross OA. Early-Onset Parkinson's Disease: Creating the Right Environment for a Genetic Disorder. J Parkinsons Dis. 2022; 12(8):2353-2367.
    View PubMed
  18. Faroqi AH, Lim MJ, Kee EC, Lee JH, Burgess JD, Chen R, Di Virgilio F, Delenclos M, McLean PJ. In Vivo Detection of Extracellular Adenosine Triphosphate in a Mouse Model of Traumatic Brain Injury. J Neurotrauma. 2021 Mar; 38 (5):655-664 Epub 2020 Oct 19
    View PubMed
  19. Bhattarai Y, Si J, Pu M, Ross OA, McLean PJ, Till L, Moor W, Grover M, Kandimalla KK, Margolis KG, Farrugia G, Kashyap PC. Role of gut microbiota in regulating gastrointestinal dysfunction and motor symptoms in a mouse model of Parkinson's disease. Gut Microbes. 2021 Jan 1; 13 (1):1866974
    View PubMed
  20. Soto-Beasley AI, Walton RL, Valentino RR, Hook PW, Labbe C, Heckman MG, Johnson PW, Goff LA, Uitti RJ, McLean PJ, Springer W, McCallion AS, Wszolek ZK, Ross OA. Screening non-MAPT genes of the Chr17q21 H1 haplotype in Parkinson's disease. Parkinsonism Relat Disord. 2020 Sep; 78:138-144 Epub 2020 Aug 01
    View PubMed
  21. Zhao N, Attrebi ON, Ren Y, Qiao W, Sonustun B, Martens YA, Meneses AD, Li F, Shue F, Zheng J, Van Ingelgom AJ, Davis MD, Kurti A, Knight JA, Linares C, Chen Y, Delenclos M, Liu CC, Fryer JD, Asmann YW, McLean PJ, Dickson DW, Ross OA, Bu G. APOE4 exacerbates alpha-synuclein pathology and related toxicity independent of amyloid. Sci Transl Med. 2020 Feb 5; 12 (529)
    View PubMed
  22. Park JH, Burgess JD, Faroqi AH, DeMeo NN, Fiesel FC, Springer W, Delenclos M, McLean PJ. Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway. Mol Neurodegener. 2020 Jan 13; 15 (1):5
    View PubMed
  23. Kiechle M, von Einem B, Hofs L, Voehringer P, Grozdanov V, Markx D, Parlato R, Wiesner D, Mayer B, Sakk O, Baumann B, Lukassen S, Liss B, Ekici AB, Ludolph AC, Walther P, Ferger B, McLean PJ, Falkenburger BH, Weishaupt JH, Danzer KM. In Vivo Protein Complementation Demonstrates Presynaptic alpha-Synuclein Oligomerization and Age-Dependent Accumulation of 8-16-mer Oligomer Species. Cell Rep. 2019 Nov 26; 29 (9):2862-2874.e9
    View PubMed
  24. Grozdanov V, Bousset L, Hoffmeister M, Bliederhaeuser C, Meier C, Madiona K, Pieri L, Kiechle M, McLean PJ, Kassubek J, Behrends C, Ludolph AC, Weishaupt JH, Melki R, Danzer KM. Increased Immune Activation by Pathologic alpha-Synuclein in Parkinson's Disease. Ann Neurol. 2019 Oct; 86 (4):593-606 Epub 2019 Aug 15
    View PubMed
  25. Delenclos M, Burgess JD, Lamprokostopoulou A, Outeiro TF, Vekrellis K, McLean PJ. Cellular models of alpha-synuclein toxicity and aggregation. J Neurochem. 2019 Sep; 150 (5):566-576 Epub 2019 July 30
    View PubMed
  26. Sun J, Carlson-Stevermer J, Das U, Shen M, Delenclos M, Snead AM, Koo SY, Wang L, Qiao D, Loi J, Petersen AJ, Stockton M, Bhattacharyya A, Jones MV, Zhao X, McLean PJ, Sproul AA, Saha K, Roy S. CRISPR/Cas9 editing of APP C-terminus attenuates beta-cleavage and promotes alpha-cleavage. Nat Commun. 2019 Jan 3; 10 (1):53 Epub 2019 Jan 03
    View PubMed
  27. Wang B, Underwood R, Kamath A, Britain C, McFerrin MB, McLean PJ, Volpicelli-Daley LA, Whitaker RH, Placzek WJ, Becker K, Ma J, Yacoubian TA. "14-3-3 proteins reduce cell-to-cell transfer and propagation of pathogenic alpha-synuclein": Erratum The Journal of Neuroscience. 2018 Nov 21; 38 (47):10236
  28. Wang B, Underwood R, Kamath A, Britain C, McFerrin MB, McLean PJ, Volpicelli-Daley LA, Whitaker RH, Placzek WJ, Becker K, Ma J, Yacoubian TA. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic alpha-Synuclein. J Neurosci. 2018 Sep 19; 38 (38):8211-8232 Epub 2018 Aug 09
    View PubMed
  29. Cai W, Feng D, Schwarzschild MA, McLean PJ, Chen X. Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice. EBioMedicine. 2018 Mar; 29:13-22 Epub 2018 Jan 31
    View PubMed
  30. Jiang P, Gan M, Yen SH, McLean PJ, Dickson DW. Impaired endo-lysosomal membrane integrity accelerates the seeding progression of alpha-synuclein aggregates. Sci Rep. 2017 Aug 9; 7 (1):7690 Epub 2017 Aug 09
    View PubMed
  31. von Einem B, Eschbach J, Kiechle M, Wahler A, Thal DR, McLean PJ, Weishaupt JH, Ludolph AC, von Arnim CAF, Danzer KM. The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (alpha-syn) oligomerization and secretion. Aging (Albany NY). 2017 Jul 15; 9 (7):1677-1697
    View PubMed
  32. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017 Jul 4; 89 (1):88-100 Epub 2017 June 07
    View PubMed
  33. Delenclos M, Faroqi AH, Yue M, Kurti A, Castanedes-Casey M, Rousseau L, Phillips V, Dickson DW, Fryer JD, McLean PJ. Neonatal AAV delivery of alpha-synuclein induces pathology in the adult mouse brain. Acta Neuropathol Commun. 2017 Jun 23; 5 (1):51 Epub 2017 June 23
    View PubMed
  34. Jiang P, Gan M, Yen SH, McLean PJ, Dickson DW. Histones facilitate alpha-synuclein aggregation during neuronal apoptosis. Acta Neuropathol. 2017 Apr; 133 (4):547-558 Epub 2016 Dec 21
    View PubMed
  35. Delenclos M, Trendafilova T, Mahesh D, Baine AM, Moussaud S, Yan IK, Patel T, McLean PJ. Investigation of Endocytic Pathways for the Internalization of Exosome-Associated Oligomeric Alpha-Synuclein. Front Neurosci. 2017; 11:172 Epub 2017 Mar 30
    View PubMed
  36. Levin J, Hillmer AS, Hogen T, McLean PJ, Giese A. Intracellular formation of alpha-synuclein oligomers and the effect of heat shock protein 70 characterized by confocal single particle spectroscopy. Biochem Biophys Res Commun. 2016 Aug 12; 477 (1):76-82 Epub 2016 June 07
    View PubMed
  37. Jarvela TS, Lam HA, Helwig M, Lorenzen N, Otzen DE, McLean PJ, Maidment NT, Lindberg I. The neural chaperone proSAAS blocks alpha-synuclein fibrillation and neurotoxicity. Proc Natl Acad Sci U S A. 2016 Aug 9; 113 (32):E4708-15 Epub 2016 July 25
    View PubMed
  38. Jiang P, Gan M, Yen SH, Moussaud S, McLean PJ, Dickson DW. Proaggregant nuclear factor(s) trigger rapid formation of alpha-synuclein aggregates in apoptotic neurons. Acta Neuropathol. 2016 Jul; 132 (1):77-91 Epub 2016 Feb 02
    View PubMed
  39. Delenclos M, Jones DR, McLean PJ, Uitti RJ. Biomarkers in Parkinson's disease: Advances and strategies. Parkinsonism Relat Disord. 2016 Jan; 22 Suppl 1:S106-10 Epub 2015 Sept 30
    View PubMed
  40. Helferich AM, McLean PJ, Weishaupt JH, Danzer KM. Commentary: alpha-synuclein interacts with SOD1 and promotes its oligomerization. J Neurol Neuromedicine. 2016; 1 (7):28-30
    View PubMed
  41. Helferich AM, Ruf WP, Grozdanov V, Freischmidt A, Feiler MS, Zondler L, Ludolph AC, McLean PJ, Weishaupt JH, Danzer KM. alpha-synuclein interacts with SOD1 and promotes its oligomerization. Mol Neurodegener. 2015 Dec 8; 10:66 Epub 2015 Dec 08
    View PubMed
  42. Jones DR, Delenclos M, Baine AT, DeTure M, Murray ME, Dickson DW, McLean PJ. Transmission of Soluble and Insoluble alpha-Synuclein to Mice. J Neuropathol Exp Neurol. 2015 Dec; 74 (12):1158-69
    View PubMed
  43. Delenclos M, Moussaud S, McLean PJ. Untangling a role for tau in synucleinopathies. Biol Psychiatry 2015 Nov 15; 78 (10):666-7
    View PubMed
  44. Labbe C, Ogaki K, Lorenzo-Betancor O, Soto-Ortolaza AI, Walton RL, Rayaprolu S, Fujioka S, Murray ME, Heckman MG, Puschmann A, McCarthy A, Lynch T, Siuda J, Opala G, Rudzinska M, Krygowska-Wajs A, Barcikowska M, Czyzewski K, Sanotsky Y, Rektorova I, McLean PJ, Rademakers R, Ertekin-Taner N, Hassan A, Ahlskog JE, Boeve BF, Petersen RC, Maraganore DM, Adler CH, Ferman TJ, Parisi JE, Graff-Radford NR, Uitti RJ, Wszolek ZK, Dickson DW, Ross OA. Role for the microtubule-associated protein tau variant p.A152T in risk of alpha-synucleinopathies. Neurology. 2015 Nov 10; 85 (19):1680-6 Epub 2015 Sept 02
    View PubMed
  45. Labbe C, Ogaki K, Lorenzo-Betancor O, Soto-Ortolaza AI, Walton RL, Rayaprolu S, Fujioka S, Murray ME, Heckman MG, Puschmann A, McCarthy A, Lynch T, Siuda J, Opala G, Rudzinska M, Krygowska-Wajs A, Barcikowska M, Czyzewski K, Sanotsky Y, Rektorova I, McLean PJ, Rademakers R, Ertekin-Taner N, Hassan A, Ahlskog JE, Boeve BF, Petersen RC, Maraganore DM, Adler CH, Ferman TJ, Parisi JE, Graff-Radford NR, Uitti RJ, Wszolek ZK, Dickson DW, Ross OA. "Role for the microtubule-associated protein tau variant p.A152T in risk of alpha-synucleinopathies": Correction Neurology. 2015 Nov; 85: (19)1728.
  46. Lindberg I, Shorter J, Wiseman RL, Chiti F, Dickey CA, McLean PJ. Chaperones in Neurodegeneration. J Neurosci. 2015 Oct 14; 35 (41):13853-9
    View PubMed
  47. Lorenzo-Betancor O, Ogaki K, Soto-Ortolaza AI, Labbe C, Walton RL, Strongosky AJ, van Gerpen JA, Uitti RJ, McLean PJ, Springer W, Siuda J, Opala G, Krygowska-Wajs A, Barcikowska M, Czyzewski K, McCarthy A, Lynch T, Puschmann A, Rektorova I, Sanotsky Y, Vilarino-Guell C, Farrer MJ, Ferman TJ, Boeve BF, Petersen RC, Parisi JE, Graff-Radford NR, Dickson DW, Wszolek ZK, Ross OA. DNAJC13 p.Asn855Ser mutation screening in Parkinson's disease and pathologically confirmed Lewy body disease patients. Eur J Neurol. 2015 Sep; 22 (9):1323-5
    View PubMed
  48. Yue M, Hinkle KM, Davies P, Trushina E, Fiesel FC, Christenson TA, Schroeder AS, Zhang L, Bowles E, Behrouz B, Lincoln SJ, Beevers JE, Milnerwood AJ, Kurti A, McLean PJ, Fryer JD, Springer W, Dickson DW, Farrer MJ, Melrose HL. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis. 2015 Jun; 78:172-95. Epub 2015 Mar 31.
    View PubMed
  49. Moussaud S, Malany S, Mehta A, Vasile S, Smith LH, McLean PJ. Targeting alpha-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies. Expert Opin Ther Targets. 2015 May; 19 (5):589-603 Epub 2015 Mar 18
    View PubMed
  50. Gan M, Moussaud S, Jiang P, McLean PJ. Extracellular ATP induces intracellular alpha-synuclein accumulation via P2X1 receptor-mediated lysosomal dysfunction. Neurobiol Aging. 2015 Feb; 36 (2):1209-20 Epub 2014 Nov 05
    View PubMed
  51. Delenclos M, Trendafilova T, Jones DR, Moussaud S, Baine AM, Yue M, Hirst WD, McLean PJ. A Rapid, Semi-Quantitative Assay to Screen for Modulators of Alpha-Synuclein Oligomerization Ex vivo. Front Neurosci. 2015; 9:511 Epub 2016 Jan 19
    View PubMed
  52. Eschbach J, von Einem B, Muller K, Bayer H, Scheffold A, Morrison BE, Rudolph KL, Thal DR, Witting A, Weydt P, Otto M, Fauler M, Liss B, McLean PJ, Spada AR, Ludolph AC, Weishaupt JH, Danzer KM. Mutual exacerbation of peroxisome proliferator-activated receptor gamma coactivator 1alpha deregulation and alpha-synuclein oligomerization. Ann Neurol. 2015 Jan; 77(1):15-32. Epub 2014 Dec 19.
    View PubMed
  53. Moussaud S, Jones DR, Moussaud-Lamodiere EL, Delenclos M, Ross OA, McLean PJ. Alpha-synuclein and tau: teammates in neurodegeneration? Mol Neurodegener. 2014 Oct 29; 9:43
    View PubMed
  54. Wang L, Das U, Scott DA, Tang Y, McLean PJ, Roy S. alpha-synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr Biol. 2014 Oct 6; 24 (19):2319-26 Epub 2014 Sept 25
    View PubMed
  55. Winslow AR, Moussaud S, Zhu L, Post KL, Dickson DW, Berezovska O, McLean PJ. Convergence of pathology in dementia with Lewy bodies and Alzheimer's disease: a role for the novel interaction of alpha-synuclein and presenilin 1 in disease. Brain. 2014 Jul; 137 (Pt 7):1958-70 Epub 2014 May 24
    View PubMed
  56. Dimant H, Kalia SK, Kalia LV, Zhu LN, Kibuuka L, Ebrahimi-Fakhari D, McFarland NR, Fan Z, Hyman BT, McLean PJ. Direct detection of alpha synuclein oligomers in vivo Acta Neuropathologica Communications. 2014; 2: (1)6.
  57. McFarland NR, Dimant H, Kibuuka L, Ebrahimi-Fakhari D, Desjardins CA, Danzer KM, Danzer M, Fan Z, Schwarzschild MA, Hirst W, McLean PJ. Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not alpha-synuclein-induced neuronal cell loss. PLoS One. 2014; 9 (1):e86048 Epub 2014 Jan 20
    View PubMed
  58. Gan M, Jiang P, McLean P, Kanekiyo T, Bu G. Low-density lipoprotein receptor-related protein 1 (LRP1) regulates the stability and function of GluA1 alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor in neurons. PLoS One. 2014; 9 (12):e113237 Epub 2014 Dec 12
    View PubMed
  59. Jones DR, Moussaud S, McLean P. Targeting heat shock proteins to modulate alpha-synuclein toxicity. Ther Adv Neurol Disord. 2014 Jan; 7 (1):33-51
    View PubMed
  60. Dimant H, Zhu L, Kibuuka LN, Fan Z, Hyman BT, McLean PJ. Direct visualization of CHIP-mediated degradation of alpha-synuclein in vivo: implications for PD therapeutics. PLoS One. 2014; 9 (3):e92098 Epub 2014 Mar 24
    View PubMed
  61. Neal KL, Shakerdge NB, Hou SS, Klunk WE, Mathis CA, Nesterov EE, Swager TM, McLean PJ, Bacskai BJ. Development and screening of contrast agents for in vivo imaging of Parkinson's disease. Mol Imaging Biol. 2013 Oct; 15(5):585-95.
    View PubMed
  62. Kalia LV, Kalia SK, McLean PJ, Lozano AM, Lang AE. alpha-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol. 2013 Feb; 73(2):155-69. Epub 2012 Dec 7
    View PubMed
  63. Dimant H, Kalia SK, Kalia LV, Zhu LN, Kibuuka L, Ebrahimi-Fakhari D, McFarland NR, Fan Z, Hyman BT, McLean PJ. Direct detection of alpha synuclein oligomers in vivo. Acta Neuropathol Commun. 2013; 1(1):6. Epub 2013 May 09.
    View PubMed
  64. Dimant H, Ebrahimi-Fakhari D, McLean PJ. Molecular chaperones and co-chaperones in Parkinson disease. Neuroscientist. 2012 Dec; 18(6):589-601. Epub 2012 Jul 24.
    View PubMed
  65. Ebrahimi-Fakhari D, Wahlster L, McLean PJ. Protein degradation pathways in Parkinson's disease: curse or blessing. Acta Neuropathol. 2012 Aug; 124(2):153-72. Epub 2012 Jun 29.
    View PubMed
  66. Klucken J, Poehler AM, Ebrahimi-Fakhari D, Schneider J, Nuber S, Rockenstein E, Schlotzer-Schrehardt U, Hyman BT, McLean PJ, Masliah E, Winkler J. Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway. Autophagy. 2012 May 01; 8(5):754-66.
    View PubMed
  67. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Banhegyi G, Bartholomew CR, Bassham DC, Bast RC Jr, Batoko H, Bay BH, Beau I, Bechet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahova M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Choi KS, Choi ME, Chouaib S, Choubey D, Choubey V, Chu CT, Chuang TH, Chueh SH, Chun T, Chwae YJ, Chye ML, Ciarcia R, Ciriolo MR, Clague MJ, Clark RS, Clarke PG, Clarke R, Codogno P, Coller HA, Colombo MI, Comincini S, Condello M, Condorelli F, Cookson MR, Coombs GH, Coppens I, Corbalan R, Cossart P, Costelli P, Costes S, Coto-Montes A, Couve E, Coxon FP, Cregg JM, Crespo JL, Cronje MJ, Cuervo AM, Cullen JJ, Czaja MJ, D'Amelio M, Darfeuille-Michaud A, Davids LM, Davies FE, De Felici M, de Groot JF, de Haan CA, De Martino L, De Milito A, De Tata V, Dong Z, et al, Garcia L, Ghosh P, Harris AL, Jackson WT, Jiang H, Jiang H, Jimenez A, Lee GM, Li F, McLean PJ, Prasad A, Reed JC, Ryan KM, Sanchez AM, Sinicrope FA, Sood AK, Springer W, Tang D, Wang F, Wang G, Wang J, Xu X, Yu L, Zhang J, Zhang XD, Zhu X. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr; 8 (4):445-544
    View PubMed
  68. Donmez G, Arun A, Chung CY, McLean PJ, Lindquist S, Guarente L. SIRT1 protects against alpha-synuclein aggregation by activating molecular chaperones. J Neurosci. 2012 Jan 4; 32(1):124-32.
    View PubMed
  69. Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu L, Vanderburg CR, McLean PJ. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener. 2012; 7:42. Epub 2012 Aug 24.
    View PubMed
  70. Ebrahimi‐Fakhari D, McLean PJ, Unni VK. Alpha‐synuclein's degradation in vivo: opening a new (cranial) window on the roles of degradation pathways in Parkinson's disease. Autophagy. 2012; 8(2):281-3 Epub 2012 Feb 1.
  71. Danzer KM, McLean PJ. Drug targets from genetics: alpha-synuclein. CNS Neurol Disord Drug Targets. 2011 Sep 1; 10(6):712-23.
    View PubMed
  72. Hashimoto T, Adams KW, Fan Z, McLean PJ, Hyman BT. Characterization of oligomer formation of amyloid-beta peptide using a split-luciferase complementation assay. J Biol Chem. 2011 Aug 5; 286(31):27081-91. Epub 2011 Jun 07.
    View PubMed
  73. Unni VK, Ebrahimi-Fakhari D, Vanderburg CR, McLean PJ, Hyman BT. Studying protein degradation pathways in vivo using a cranial window-based approach. Methods. 2011 Mar; 53(3):194-200. Epub 2010 Dec 25.
    View PubMed
  74. Danzer KM, Ruf WP, Putcha P, Joyner D, Hashimoto T, Glabe C, Hyman BT, McLean PJ. Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J. 2011 Jan; 25(1):326-36. Epub 2010 Sep 27.
    View PubMed
  75. Kalia LV, Kalia SK, Chau H, Lozano AM, Hyman BT, McLean PJ. Ubiquitinylation of alpha-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5). PLoS One. 2011; 6(2):e14695. Epub 2011 Feb 16.
    View PubMed
  76. Mazzulli JR, Xu Y‐H, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D. Gaucher disease glucocerebrosidase and alpha‐synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011; 146(1):37-52 Epub 2011 Jun 23.
  77. Ebrahimi‐Fakhari D, Cantuti‐Castelvetri I, Fan Z, Rockenstein E, Masliah E, Hyman BT, McLean PJ, Unni VK. Distinct Roles in vivo for the ubiquitin‐proteasome system and the autophagy‐lysosomal pathway in the degradation of alpha‐synuclein. J Neurosci. 2011; 31(41):14508-20.
  78. Ebrahimi‐Fakhari D, Wahlster L, McLean PJ. Molecular Chaperones in Parkinson's Disease - Present and Future. J Parkinson's Dis. 2011; 1(4):299-320.
  79. Kalia SK, Kalia LV, McLean PJ. Molecular chaperones as rational drug targets for Parkinson's disease therapeutics. CNS Neurol Disord Drug Targets. 2010 Dec; 9(6):741-53.
    View PubMed
  80. Unni VK, Weissman TA, Rockenstein E, Masliah E, McLean PJ, Hyman BT. In vivo imaging of alpha-synuclein in mouse cortex demonstrates stable expression and differential subcellular compartment mobility. PLoS One. 2010; 5(5):e10589. Epub 2010 May 11.
    View PubMed
  81. Hillmer AS, Putcha P, Levin J, Hogen T, Hyman BT, Kretzschmar H, McLean PJ, Giese A. Converse modulation of toxic alpha-synuclein oligomers in living cells by N'-benzylidene-benzohydrazide derivates and ferric iron. Biochem Biophys Res Commun. 2010 Jan 1; 391(1):461-6. Epub 2009 Nov 13.
    View PubMed
  82. Putcha P, Danzer KM, Kranich LR, Scott A, Silinski M, Mabbett S, Hicks CD, Veal JM, Steed PM, Hyman BT, McLean PJ. Brain permeable small molecule inhibitors of Hsp90 prevent alpha‐synuclein oligomer formation and rescue alpha‐synuclein‐induced toxicity. J Pharm Exp Ther. 2010; 332(3):849-57 Epub 2009 Nov 24.
  83. McFarland NR, Lee JS, Hyman BT, McLean PJ. Comparison of Transduction Efficiency of Recombinant AAV Serotypes 1, 2, 5, and 8 in the Rat Nigrostriatal System. J Neurochem. 2009; 109(3):838-45 Epub 2009 Feb 24.
  84. McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, Hyman BT, McLean PJ. Alpha‐synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J Neuropathol Exp Neurol. 2009; 68(5):515-24.
  85. Outeiro TF, Klucken J, Bercury K, Tetzlaff JE, Putcha P, Oliveira LMA, Quintas A, McLean PJ, Hyman BT. Dopamine‐Induced Conformational Changes in Alpha‐Synuclein. PLoS ONE. 2009; 4(9):e6906.
  86. Chen L, Periquet M, Wang X, Negro A, McLean PJ, Hyman BT, Feany M. Serine Phosphorylation of alphasynuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest. 2009; 119(11):3257-65 Epub 2009 Oct 12.
  87. Yacoubian TA, Cantuti-Castelvetri I, Bouzou B, Asteris G, McLean PJ, Hyman BT, Standaert DG. Transcriptional dysregulation in a transgenic model of Parkinson disease. Neurobiol Dis. 2008 Mar; 29(3):515-28. Epub 2007 Nov 28.
    View PubMed
  88. Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, Carvalho F, Hyman BT, McLean PJ. Formation of toxic oligomeric alpha‐synuclein species in living cells. PLoS ONE. 2008; 3(4):e1867.
  89. Tetzlaff JE, Putcha P, Outeiro TF, Ivanov A, Berezovska O, Hyman BT, McLean PJ. Chip targets toxic alphasynuclein oligomers for degradation. J Biol Chem. 2008; 283(26):17962-8 Epub 2008 Apr 25.
  90. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, Ng J, Schulz‐Schaeffer W, Kretzschmar HA, McLean PJ, Trenkwalder C, Sarracino DA, Vonsattel JP, Locascio JJ, El‐Agnaf OM, Schlossmacher MG. Direct quantification of CSF alpha‐synuclein by ELISA and first cross‐sectional study in patients with neurodegeneration. Exp Neurol. 2008; 213(2):315-25 Epub 2008 Jun 14.
  91. Theodore S, Cao S, McLean PJ, Standaert DG. Targeted overexpression of human α‐synuclein triggers microglial activation and an adaptive immune respone in a mouse model of Parkinson's disease. J Neuropathol Exp Neurol. 2008; 67(12):1149-58.
  92. St Martin JL, Klucken J, Outeiro TF, Nguyen P, Keller‐McGandy C, Cantuti‐Castelvetri I, Grammatopoulos TN, Standaert DG, Hyman BT, McLean PJ. Dopaminergic neuron loss and upregulation of chaperone protein mRNA induced by targeted overexpression of alpha‐synuclein in mouse substantia nigra. J Neurochem. 2007; 100(6):1449-57 Epub 2007 Jan 4.
  93. Outeiro TF, Kontopoulos E, Altman S, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet J‐C, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT, Kazantsev A. Sirtuin 2 Inhibitors Rescue Alpha‐Synuclein‐Mediated Toxicity in Models of Parkinson's Disease. Science. 2007; 317:516-9 Epub 2007 Jun 21.
  94. Klucken J, Ingelsson M, Shin Y, Irizarry MC, Hedley‐Whyte ET, Frosch M, Growdon J, McLean PJ, Hyman BT. Clinical and biochemical correlates of insoluble alpha‐synuclein in Dementia with Lewy Bodies. Acta Neuropathol. 2006; 111(2):101-8 Epub 2006 Feb 16.
  95. Giaime E, Sunyach C, Herrant M, Grosso S, Auberger P, McLean PJ, Checler F, Alves da Costa F. Caspase 3‐derived C‐terminal product of synphilin‐1 displays anti‐apoptotic function via modulation of the p53‐dependent cell death pathway. J Biol Chem. 2006; 28(17):11515-22 Epub 2006 Feb 22.
  96. Bodner R, Outeiro TF, Altman S, Maxwell MM, Cho SH, Hyman BT, McLean PJ, Young AB, Housman DE, Kazantsev AG. A novel approach to therapeutic interventions for Huntington's and Parkinson's diseases. Proc Natl Acad Sci. 2006; 103(11):4246-51 Epub 2006 Mar 6.
  97. Klucken J, Outeiro TF, Nguyen P, McLean PJ, Hyman BT. Detection of novel intracellular α‐synuclein oligomeric species by fluorescence lifetime imaging. FASEB J. 2006; 20(12):2050-7.
  98. Outeiro TF, Klucken J, Strathearn KE, Liu F, Nguyen P, Rochet J‐C, Hyman BT, McLean PJ. Small heat shock proteins protect against alpha‐synuclein‐induced toxicity and aggregation. Biochem Biophys Res Comm. 2006; 351(3):631-8 Epub 2006 Oct 26.
  99. Shin Y, Klucken J, Patterson C, Hyman BT, McLean PJ. The co‐chaperone carboxyl terminus of Hsp70‐interacting Protein (CHIP) mediates α‐synuclein degradation decisions between proteasomal and lysosomal pathways. J Biol Chem. 2005; 280(25):23727-34.
  100. Spires TL, Meyer‐Leuhmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT. Dendritic spine abnormalities in APP transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neuroscience. 2005; 25:7278-87.
  101. Cantuti‐Castelvetri I, Klucken J, Ingelsson M, Ramasamy K, McLean PJ, Frosch MP, Hyman BT, Standaert DG. Alpha‐synuclein and chaperones in dementia with Lewy bodies. J Neuropathol Exp Neurol. 2005; 64(12):1058-66.
  102. Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. Hsp70 reduces alpha‐synuclein aggregation and toxicity. J Biol Chem. 2004; 279:25497-502.
  103. McLean PJ, Klucken J, Shin Y, Hyman BT. Geldanamycin induces Hsp70 and prevents α‐synuclein aggregation and toxicity in vitro. Biochem Biophys Res Comm. 2004; 321(3):665-9.
  104. Klucken J, Shin Y, Hyman BT, McLean PJ. A single amino acid substitution differentiates Hsp70 dependent effects on α‐synuclein degradation and toxicity. Biochem Biophys Res Comm. 2004; 325(1):367-74.
  105. Klucken J, McLean PJ, Gomez‐Tortosa E, Ingelsson M, Hyman BT. Neuritic alterations and neural system dysfunction in Alzheimer's disease and dementia with Lewy bodies. Neurochem Res. 2003; 11:1683-91.
  106. McLean PJ, Hyman BT. An alternatively spliced form of rodent α‐synuclein forms intracellular inclusions in vitro: role of the carboxy‐terminus in α‐synuclein aggregation. Neurosci Letts. 2002; 323(3):219-23.
  107. McLean PJ, Kawamata H, Shariff S, Hewett J, Sharma N, Ueda K, Breakefield XO, Hyman BT. TorsinA and heat shock proteins act as molecular chaperones: suppression of α‐synuclein aggregation in vitro. J Neurochem. 2002; 83:846-54.
  108. McLean PJ, Kawamata H, Hyman BT. α‐SynucleinEGFP fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience. 2001; 104:901-12.
  109. Kawamata H, McLean PJ, Sharma N, Hyman BT. Interaction of α‐synuclein and synphilin‐1: Effect of Parkinson's disease associated mutations. J Neurochem. 2001; 77(3):929-34.
  110. Sharma N, McLean PJ, Kawamata H, Hyman BT. Alpha‐synuclein has an altered conformation and shows a tight intermolecular interaction with ubiquitin in Lewy bodies. Acta Neuropathol. 2001; 104:329-34.
  111. Sharma N, Hewett J, Ozelius LJ, Ramesh V, McLean PJ, Breakefield XO, Hyman BT. A close association of torsinA and alpha‐synuclein in Lewy bodies: A fluorescence energy transfer study. Am J Pathol. 2001; 59:339-44.
  112. McLean PJ, Shpektor D, Bandyopandhyay S, Russek SJ, Farb DH. A minimal promoter for the GABAA receptor α6 subunit gene controls tissue specificity. J Neurochem. 2000; 74(5):1858-69.
  113. Berezovska O, Jack C, McLean P, Aster JC, Hicks C, Xia W, Wolfe MS, Kimberly WT, Weinmaster G, Selkoe DJ, Hyman BT. Aspartate mutations in presenilin and γ‐secretase inhibitors both impair Notch1 proteolysis and nuclear translocation with relative preservation of Notch signaling. J Neurochem. 2000; 75(2):583-93.
  114. McLean PJ, Kawamata H, Ribich S, Hyman BT. Membrane association and protein conformation of α‐synuclein in intact neurons: Effect of Parkinson disease linked mutations. J Biol Chem. 2000; 275(12):8812-6.
  115. Berezovska O, McLean P, Knowles R, Lu FM, Lux SE, Hyman BT. Notch transfection affects neurite outgrowth in post‐mitotic primary neurons. Neuroscience. 1999; 93(2):433-9.
  116. Berezovska O, Frosch M, McLean P, Knowles R, Koo E, Kang D, Lu FM, Lux SE, Shen J, Tonegawa S, Hyman BT. The Alzheimer‐related gene Presenilin 1 facilitates Notch 1 effect on neurite outgrowth in primary mammalian neurons. Molecular Brain Research. 1999; 69(2):273-80.
  117. McLean PJ, Farb DH, Russek SJ. Mapping of the α4 subunit gene (GABRA4) to human chromosome 4 defines an α2‐α4‐β1‐γ1 gene cluster: Further evidence that modern GABAA receptor gene clusters are derived from an ancestral cluster. Genomics. 1995; 26:580-6.